Dr. Yeung Sai-ching

Dr. Yeung Sai-ching

Professor of Medicine

University of Texas
Texas, United States of America

plus Speciality




1. 1987 – 1991: MD, Medicine; Saint Louis University School of Medicine
2. 1983 – 1987: PhD, Biology; University of Houston
3. 1978 – 1983: BS, Pharmacy; University of Houston
4. 1972 – 1978: Wah Yan College Kowloon

Academic positions:


1. August 2013 – Present: Professor of Medicine; The University of Texas MD Anderson Cancer Center
2. March 2011 – Present: Director of Research; Department of Emergency Medicine, UT MD Anderson Cancer Center
3. August 2006 – August 2013: Associate Internist and Associate Professor of Medicine; The University of Texas M. D. Anderson Cancer Center
4. August 1997 – August 2006: Assistant Internist and Assistant Professor of Medicine; The University of Texas M. D. Anderson Cancer Center


1. Yeung & Escalante. (Editors). Oncologic Emergency. B. C. Decker Inc., Hamilton, Ontario, Canada, 2002.
2. Yeung, Escalante, & Gagel. (Editors). Medicine Care of Cancer Patients. B. C. Decker Inc., Hamilton, Ontario, Canada, 2009.
3. Esteva, et al. Safety and pharmacokinetic study of exemestane in combination with metformin and rosiglitazone in overweight and obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol. 71:63-72, 2013.
4. Yeung, et al. Fatal acute monocytic leukemia with t(6;11)(q27;q23) translocation and KRAS mutation. J Clinical Pathology. 66:73-5, 2013.
5. Hanzelka, et al. Implementation of Modified Early Goal Directed Therapy for Sepsis in the Emergency Center of a Comprehensive Cancer Center. Supportive Care Cancer. 21:727-34, 2013.


1. Chen, et al. Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene 28:2581-2592, 2009.
2. Li, et al. Gastroenterology 137:482-488, 2009.
3. Gully, et al. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol. Cancer. 9:42, 2010.
4. Feng, et al. Impact of antidiabetic drugs on cancer in type 2 diabetic conditions. J. Cell. Molec. Med. 15:825-836, 2011.
5. Zhao, et al. COP9 signalosome subunit 6 promotes tumorigenesis through stabilization of MDM2. J. Clin. Invest. 121:851-865, 2011.
6. Xue, et al. HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53. Cell Cycle. 11:4181-90; 2012.
7. Teng, et al. FBXW7 is involved in Aurora B degradation. Cell Cycle. 11:4059-68, 2012.
8. Chen, et al. CDK inhibitor p57Kip2 is negatively regulated by COP9 signalosome subunit 6. Cell Cycle. 11:4633-41, 2012.


1. Phi Kappa Phi Honor Society (Life-time Member since 1982)
2. Research Excellence Award, University of Houston, Biology Department, 1986
3. Wendell Griffith Award in Biochemistry, St. Louis University, School of Medicine, 1991
4. Strathmore’s WHO’s WHO (Life-time Member since 2001)
5. Fellow of American College of Physicians – American Society of Internal Medicine Inducted in April 2002
6. Continental WHO’s WHO (Fellow Lifetime Member since 2006)
7. Vietnam Education Foundation US Faculty Scholar 2013

Research interests:


Any other information:


1. Eskin, A., Yeung, S. J., and Klass, M.  Requirement for protein synthesis in the regulation of a circadian rhythm by serotonin.  Proc. Natl. Acad. Sci., U.S.A., 81:7637-41, 1984.
2. Yeung, S. and Eskin, A.  Involvement of a specific protein in the regulation of a circadian rhythm in Aplysia eye.  Proc. Natl, Acad. Sci., U.S. A., 84:279-83, 1987.
3. Yeung, S. J. and Eskin, A.  Responses of the circadian system in the Aplysia eye to inhibitors of protein synthesis.  J. Biol. Rhythms, 3:225-36, 1988.
4. Raju, U., Yeung, S. J., and Eskin, A.  Involvement of proteins in light resetting ocular circadian oscillators of Aplysia.  Am. J. Physiol., 258:R256-62, 1990.
5. Bem, W.T., Yeung, S. J., Belcheva, M., Barg, J., and Coscia, C. J.  Age-dependent changes in the subcellular distribution of rat brain mu-opioid receptors and GTP binding regulatory proteins.  J. Neurochem., 57:1470-77, 1991.
6. Raju, U., Nunez-Regueiro, M., Cook, R., Kaetzel, M. A., Yeung, S. J., and Eskin, A.  Identification of an annexin-like protein and its possible role in the Aplysia eye circadian system.  J. Neurochem., 61:1236-45, 1993.
7. Yeung, S. J., Go, R., and Balasubramanyam, A.  Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm.  Thyroid, 5:403-5, 1995.
8. Yeung, S. J., Chen, S. H., and Chan, L.  Ubiquitin-proteasome pathway mediated intracellular degradation of apolipoprotein B.  Biochemistry, 35:13843-48, 1996.
9. Yeung, S. J., Anderson, J., Kobayashi, K., Oka, K., and Chan, L.  Production of rabbit polyclonal antibody against apobec-1 by genetic immunization.  J. Lipid Res,, 38:2627-32, 1997.
10. Yeung, S. J., Eton, O., Burton, D., Deftos, L., Sellin-Vassilopoulou, R., and Gagel, R. F.  Hypercalcemia due to parathyroid hormone-related protein secretion by melanoma.  Hormone Res., 49:288-91, 1998.
11. Yeung, S. J., Chiu, A. C., Vassilopoulou-Sellin, R., and Gagel, R.   The endocrine effects of nonhormonal antineoplastic therapy.  Endocrine Reviews 19: 144-172, 1998.
12. Liao, W.*,Yeung, S. J.*, and Chan, L.  Proteasome-mediated degradation of apolipoprotein B targets both nascent peptides cotranslationally before translocation and full-length apolipoprotein B after translocation into the endoplasmic reticulum.  J. Biol. Chem.  273: 27225-27230, 1998.  *Both considered first authors.
13. Yeung, S. J.,Xu, G., Pan J., Christgen, M., and Bamiagis, A.  Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells.  Cancer Research.  60: 650-656, 2000.
14. Yeung, S. J., McCutcheon, I. E., Schultz, P. and Gagel, R. F.   Use of long term intravenous phosphate infusion in the palliative treatment of tumor-induced osteomalacia.  J. Clin. Endocrinol. Metab. 85:549-555, 2000.
15. Xu, G. P., Pan, J., Martin, C., Yeung, S. C.  The role of angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma.  J. Clin. Endocrinol. Metab.  86:1769-1777, 2001.
16. Pan, J., Xu, G. P., Yeung, S. C.   Cytochrome c and caspase-3, caspase-8 and caspase-9 are involved in the enhanced apoptosis of anaplastic thyroid cancer cells induced by the combination of manumycin and paclitaxel.   J. Clin. Endocrinol. Metab.   86:4731-4740, 2001.
17. Hu, W., Wu, W., Yeung, S. C., Freedman, R. S., Kavanagh, J. J., Verschraegen, C. F.   Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyltransferase inhibitor.  Anticancer Res.  22:665-672, 2002.
18. Gonzales, J., Yeung, S. J., Smith, J. A.  A high performance liquid chromatography assay validation of manumycin Ain mouse plasma.   J Chromatography B.  776: 177-182, 2002.
19. Ghori, F.Y., Litofsky, D., Jamal, A., Yeung, S. C., Arem, R. and Sherman, S. I.   Socioeconomic factors and the presentation, management, and outcome of patients with differentiated thyroid carcinoma.  Thyroid.  12:1009-1016, 2002.
20. Yang, H., Pan, J., Sun, L., Yeung, S. C.  The role of p21 Waf-1 in apoptosis induced by manumycin and paclitaxel in anaplastic thyroid carcinoma.  J. Clin. Endocrinol. Metab.  88:763-772, 2003.
21. Hu, W., Wu, W., Verschraegen, C. F., Chen, L., Mao, L., Yeung, S. C., Kudelka, A. P., Freedman, R. S., Kavanagh, J. J.  Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyltransferase inhibitor.  Proteomics. 3:1904-1911, 2003.
22. Schiff, B. A., McMurphy, A. B., Jasser, S. A., Younes, M. N., Doan, D., Yigitbasi, O. G., Kim, S., Zhou, G., Mandal, M., Bekele, B. N., Holsinger, F. C., Sherman, S. I., Yeung, S. C., El-Naggar, A. K., Myers, J. N.  Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.  Clin. Cancer Res.  10:8594-602, 2004
23. She, M., Pan, J., Sun, L.,Yeung, S. C.  Enhancement of manumycin A-induced apoptosis by methoxyamine in myeloid leukemia cells.   Leukemia. 19:595-602, 2005.
24. Pan, J., She, M., Xu, Z.-X., Sun, L.,Yeung, S. C.  Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells.  Cancer Res.  65:3671-3681, 2005.
25. Pan, J., Huang, H., Sun, L., Fang, B., Yeung, S. C.Bax is the Main Mediator of Manumycin A-Induced Apoptosis in Anaplastic Thyroid Cancer Cells.  J. Clin. Endocrinol. Metab.  90:3583-3591, 2005.
26. Mambo, E., Chatterjee, A., Xing, M., Tallini, G., Haugen, B. R., Yeung, S. C.,Sukumar, S., Sidransky, D. Tumor-specific changes in mtDNA content in human cancer.  Inter. J. Cancer.   116:920-924, 2005.
27. Escalante, C., Weiser, M. A., Lam, T., Ho, V., Yeung, S. C.   Hypertension in Cancer Patients Seeking Acute Care:  An Opportunity to Intervene.   Am. J. Med. Sci.  330:120-127, 2005.
28. Dackiw A., Pan, J., Xu, G., Yeung, S. C.  Modulation of parathyroid hormone-related protein levels (PTHrP) in anaplastic thyroid cancer.  Surgery.  138:456-463, 2005.
29. She, M., Yang, H., Sun, L., Yeung, S. C.  Redox control of manumycin A-induced apoptosis in anaplastic thyroid cancer cells: Involvement of the xenobiotic apoptotic pathway.  Cancer Biol. Ther.  5:275-280, 2006.
30. She, M., Yeung, S. C.  Combining a matrix metalloproteinase inhibitor, a farnesyltransferase inhibitor, and a taxane improves survival in an anaplastic thyroid cancer model.  Cancer Lett.  238:197-201, 2006.
31. Yao, J. C., Zhang, J. X., Rashid, A., Yeung, S. C., Szklaruk, J., Hess, K., Xie, K., Ellis, L., Abbruzzese, J. L., Ajani, J. A.  Clinical and in vitro studies of imatinib in advanced carcinoid tumors.  Clin. Cancer Res. 13:234-240, 2007.
32. Yeung, S. C.,She, M., Yang, H., Pan, J., Sun, L., Chaplin, D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J. Clin. Endocrinol. Metab.  92:2902-2909, 2007.
33. Huyghe, E., Nohra, J., Caron, P., Bennet, A, Khedis, M., Otal, P., Soulie, M., Yeung, S. C., Plante, P.  Lethal posttraumatic rupture of a pheochromocytoma: lesson from a postmortem diagnosis.  Urol. Int.  79:83-85, 2007.
34. Yao, J. C., Phan, A. T., Charnsangavej, C., Yeung, S. C., Hess, K., Ng, C., Abbruzzese, J. L., Ajani, J., Chen, H.  Targeting VEGF in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide with Bevacizumab and PEG Interferon. J ClinOncol.  26:1316-1323, 2008.
35. Cheng, C., Yeung, S.-C.,Zhong, F.-T., Xiong, Y., Kuang, J.-Y., Luo, H., Pan, J.  The aneurysmal bone cyst in the first rib: two cases report.  Ann. Thoracic Surg.  85:2118-2120, 2008.
36. Feng, Y.-H., Wang, Y.-W., Yeung, S. C.Current concepts of pain management for cancer patients.  Oncol. Rev. 2:204-213, 2008.
37. Yeung, S. C., Pan, J., Lee, M.-H.  Glycolysis-the 7th hallmark of cancer: from genes to metabolism in cancer cells.  Cell. Molec. Life Sci.  65:3981-3999, 2008.
38. Pan, J., Sun, L., Lee, M.-H., Yeung, S. C.Autophagic cell death induced by farnesyltransferase inhibitors in cancer cells.  Cancer Biol. Ther. 7:1679-1684, 2008.
39. Yeung, S. C., Gully, C., Lee, M.-H.  Aurora-B kinase inhibitors for cancer chemotherapy.  Mini-Rev. Med. Chem.8:1514-1525, 2008.
40. Pan, J., Song, E., Cheng, C., Lee, M.H., Yeung, S.C. Farnesyltransferase inhibitors-induced autophagy: alternative mechanisms? Autophagy 5:129-131, 2009.
41. Chen, J., Kobayashi, M., Darmanin, S., Qiao, Y., Gully, C., Zhao, R., Shindoh, M., Kondo, S., Yeung, S.C. (co-corresponding author), Lee, M.-H.  Hypoxia-mediated upregulation of Pim-1 contributes to solid tumor formation. Am. J. Pathol. 175:400-411, 2009.
42. Chen, J., Kobayashi, M., Darmanin, S., Qiao, Y., Gully, C., Zhao, R., Yeung, S. C. (co-corresponding author), Lee, M. H. Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene 28:2581-2592, 2009.
43. Li, D., Yeung, S. C., Hassan, M. M. Abbruzzese, J. L.  Antidiabetic Therapy and Risk of Pancreatic Cancer.  Gastroenterology137:482-488, 2009.
44. Cheng, C., Wu, G., Yeung, S. C., Li, R., Bella, A. E., Pang, J., Zhong, F., Luo, H., Jin, Y., Pan, J. Serum protein profiles in myasthenia gravis. Ann. Thoracic Surg. 88:1118-1123, 2009.
45. Gully, C., Zhang, F., Chen, J., Yeung, J. A., Velazquez-Torres, G., Yeung, S. C. (co-corresponding author), Lee, M. H.   Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol. Cancer. 9:42, 2010. (Highly accessed on-line.)
46. Chen, B., Liu, C.-G., Jin, F., Sun, Y.-N., Zhao, T.-T., Zhang, L.-N., Li, S., Yeung, S. C.  The role of fine-wirelocalizationbreastbiopsy in the management of BI-RADS category 3-5 non-palpable breastlesions in northeasternChinesewomen.  Health. 2:291-294, 2010.
47. Hanzelka, K. M., Zalpour, A., Afshar-Kharghan, V., Fitousis, K., Anderlini, P., Yeung, S. C.  Severe thrombosis and acute thrombocytopenia in a cancer patient. Am. J. Hematol. 85:887-890, 2010.
48. Su, C-H., Zhao, R., Velazquez-Torres, G., Chen,J., Gully,C., Yeung, S. C. (co-corresponding author), Lee, M. H. Nuclear export regulation of COP1 by 14-3-3 sigma in response to DNA damage.  Mol. Cancer. 9:243, 2010.
49. Su, C-H., Zhao, R., Zhang, F., Qu, C., Chen, B., Feng, Y.-H., Phan, L., Chen, J., Wang, H., Wang, H., Yeung, S. C. (co-corresponding author), Lee, M. H. 14-3-3?has tumor suppressing activity via regulating COP1 stability. Cancer Res. 71:884-894, 2011.
50. Zhao, R., Yeung, S. C., Chen, J., Iwakuma, T., Su, C. H., Chen, B., Qu, C., Zhang, F., Chen, Y.-T., Lin, Y.-L., Lee, D.-F., 1, Jin, F., Zhu, R., Shaikenov, T., Sarbassov, D., Sahin, A., Wang, H., Wang, H., Lai, C. C., Lozano, G. & Lee, M.H. COP9 signalosome subunit 6 promotes tumorigenesis through stabilization of MDM2. J. Clin. Invest.121:851-865, 2011.

What I think of the idea behind WebmedCentral and WebmedCentral plus: